A Study of MG-K10 in Chronic Spontaneous Urticaria

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor control of second-generation H1 antihistamines.

Timeline

Start

2026-04-14

Primary completion

2028-03-31

Completion

2028-03-31

Drugs

Indications